Name | GW590735 |
Description | GW590735 is an effective and selective PPARα agonist with an EC50 of 4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW590735 can be used in dyslipidemia studies. |
In vivo | GW590735 (2 mg/kg; i.v.) shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively in dogs while GW590735 (2.7 mg/kg; i.v.) shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively in rats. In male C |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (104.5 mM)
|
Keywords | lipid | LDLc | GW590735 | HDLc | Peroxisome proliferator-activated receptors | PPAR | imbalance | GW 590735 | GW-590735 | Inhibitor | inhibit | triglycerides | dyslipidemia |
Inhibitors Related | PHYTOL | (S)-(+)-Ibuprofen | BADGE | Cinnamyl alcohol | Daidzein | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin |
Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Breast Cancer Compound Library | Mitochondria-Targeted Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |